EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) announced today that it has initiated a multi-dose Phase 1 clinical trial of ADL5859, a novel, orally bioavailable Delta opioid receptor agonist. The Phase 1 study is designed to investigate the safety, tolerability and pharmacokinetics of ADL5859 in healthy volunteers following twice a day dosing for seven days. This study follows the recent completion of a single dose Phase 1 study that demonstrated that the compound was well absorbed following oral administration and was generally well tolerated. Completion of the multi-dose study is targeted for the third quarter of this year.
